September 18th 2021
Current approaches to precision medicine in oncology have been fruitful, but require better integration and utilization of available resources to inform sustainable and effective drug development and clinical care, according to Andre Goy, MD.
Dr. Beltran on Use of ctDNA to Evaluate Treatment Resistance in Prostate Cancer
February 25th 2020Himisha Beltran, MD, associate professor of medicine, Lank Center for Genitourinary Oncology, Division of Molecular and Cellular Oncology, Harvard Medical School, director of Translational Research, and physician, Dana-Farber Cancer Institute, discusses the potential use of circulating tumor DNA to detect castration-resistant neuroendocrine prostate cancer.
Dr. Hamid on a Potential Biomarker of Response to Docetaxel in mHSPC
February 25th 2020Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses the potential predictive value of the luminal B subtype as a biomarker of response to docetaxel in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC).
Dr. Armstrong on AR-V7 as a Biomarker of Response to Taxane Chemotherapy in mCRPC
February 25th 2020Andrew J. Armstrong, MD, professor of medicine, associate professor in pharmacology and cancer biology, and professor in surgery at Duke University School of Medicine and a member of the Duke Cancer Institute, discusses the potential of AR-V7 as a predictive biomarker of response to taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
Dr. Levy on the Current State of Liquid Biopsies Across Tumor Types
February 22nd 2020Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the current state of liquid biopsies across tumor types.
Dr. O'Reilly on Ongoing Trials With PARP Inhibitors in Pancreatic Cancer
February 22nd 2020Eileen O'Reilly, MD, Winthrop Rockefeller Endowed Chair in Medical Oncology, co-director, Medical Initiatives, David M. Rubenstein Center for Pancreatic Cancer Research, section head, Hepatopancreaticobilary and Neuroendocrine Cancers, and medical oncologist, Memorial Sloan Kettering Cancer Center, discusses
Precision Medicine Approaches Evolving With CDK4/6, PI3K Inhibitors in HR+ Breast Cancer
February 21st 2020Sara Tolaney, MD, MPH, reflects on the encouraging findings observed with CDK4/6 inhibitors in combination with endocrine therapy in the treatment of patients with hormone receptor-positive, HER2-negative breast cancer.
Dr. Levy on Ongoing Research Evaluating the Use of Liquid Biopsies in Lung Cancer
February 8th 2020Benjamin P. Levy, MD, assistant professor of oncology and clinical director of Medical Oncology, Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses ongoing research regarding the use of liquid biopsies in lung cancer.